FDA Approves First Digital Pill: Otsuka/Proteus' Abilify MyCite
Executive Summary
Otsuka plans a slow, measured launch of Abilify MyCite, developed with Proteus Health. The product includes an ingested sensor that sends a signal to a wearable patch and an app that tracks ingestion, activity and mood to potentially improve management of psychiatric care.
You may also be interested in...
Beyond Pill Sensors, Digital Tech Can Provide Insights On How Patients Use Drugs
During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.
Keeping Track: A Second Straight Burst Of FDA Approvals
The latest drug approval and development news from our US FDA Performance Tracker.
FDA's NDA And BLA Approvals: Abilify Mycite, Mepsevii, Hemlibra
Original new drugs and biologics recently approved by US FDA.